Skip to main content
. Author manuscript; available in PMC: 2017 Dec 20.
Published in final edited form as: Med Res Arch. 2017 Mar 15;5(3):10.18103/mra.v5i3.1084. doi: 10.18103/mra.v5i3.1084

Table 2.

Incidence rate using Poisson-regression model patients treated with Cyclophosphamide.

Type of infection Number of Infection onsets Incidence rate (per100) person-Year (95% CL) Per100 person-year
Over all Infection 42 67.42 (44.34 – 102.48)
UTI 8 24.31 (11.56 – 51.14)
Pos. Blood Cx 2 0.78 (0.01 – 74.95)
Bacterial PNA 2 1.32 (0.04 – 39.89)
Pneumocystis carinii PNA 1 1.29 (0.02 – 44.28)
Mucocutaneous Fungal Infection 3 5.62 (1.07 – 29.44)
URI 14 44.65 (24.82 – 80.35)
Mucocutaneous Bacterial Infection 1 2.41 (0.21 – 27.55)
Mucocutaneous Viral Infection 8 20.8 (8.54 – 50.65)
Viral Gastroenteritis 3 9.13 (2.67 – 31.21)
*

Incidence rates are the number of events per 100 person-years.

The age and ANC adjusted Poisson-regression model were used to analyze the incidence rate and their 95% confidence intervals (95% Cls).

**

Total 42 courses of cyclophosphamide in 31 patients; denominator used is 42.